Introduction
The cardiac troponins, cardiac troponin T (cTnT) and cardiac troponin I (cTnI), are sensitive and specifi c biochemical markers of myocardial injury. The large and coherent body of evidence for the diagnostic and prognostic utility of these markers has prompted the redefi nition of the diagnosis of acute myocardial infarction (AMI) [1] and their inclusion in pathways for the management of unstable angina [2] . Furthermore, the National Academy of Clinical Biochemistry [3] and the International Federation of Clinical Chemistry have provided guidelines on the need for highly specifi c and sensitive diagnostic cardiac biomarkers, and quality specifi cations of troponin assays have been described [4] . However, clinical data for cTnI have proved more diffi cult for clinicians to interpret in their routine clinical practice. There is a range of cTnI assays commercially available, and the individual assays have different cut-off values and performance characteristics [5] . In contrast, cTnT is produced by one manufacturer (Roche Diagnostics, Lewes, UK), and has the largest and most comprehensive evidence base [5] . Evolution of the cTnT assay has produced improved methodological performance but with no changes to absolute values between the 1st-and 2nd-generation assays. This means that all of the published literature on cTnT can be directly compared, unlike the literature for cTnI where caution is required. To further improve diagnostic performance, the cTnT assay has been recalibrated using human recombinant cTnT as the calibration material to produce the 3rd-generation cTnT assay [6] . This im-munoassay, however, demonstrates altered performance characteristics [6, 7] with better precision and thus improved clinical triage and prognostic value [7] . We evaluated the impact of this change in assay formulation on currently accepted clinical decision limits.
Materials and Methods
Serum samples were obtained using SST Vaccutainer tubes (Becton-Dickinson, Oxford, UK) from 77 patients consecutively admitted to the coronary care unit according to local ethical requirements. All were male patients, 66 8 16 years old, 42 were Caucasian, 16 had a previous history of AMI and 7 had a coronary artery bypass graft. Samples were immediately and routinely analysed in the laboratory, and an aliquot was frozen and stored at -20 ° C. Following storage for a maximum of 2 weeks (within the 12-month stability recommended by the manufacturer), samples were thawed, then assayed for cTnT by two methods -initially by the existing cTnT method (2nd-generation assay) and then immediately re-assayed using the recalibrated assay (3rd-generation assay) in a second run, eliminating any possible freeze-thaw effects on results. Samples were assayed in two batches across two reagent lots. The Elecsys ® 1010 automated analyser (Roche Diagnostics) was used for all cTnT assay determinations according to the manufacturers' recommended methods. The 2nd-generation cTnT assay had a percentage coeffi cient of variation of 5.5-5.4% (at 0.32-6.0 g/l) with a measuring range of 0.01-25.0 g/l. The manufacturers state that the analytical sensitivity is 0.01 g/l and the functional sensitivity 0.05 g/l. The 3rd-generation cTnT assay percent coeffi cient of variation was 5.8-5.7% (at 0.47-11.5 g/l) with a measuring range of 0.01-25.0 g/l. The manufacturers state that the analytical sensitivity is 0.01 g/l and the functional sensitivity 0.03 g/l. Statistical analysis was by Bland-Altman, Passing and Bablok plots generated using the analyse-it ® (www.analyse-it.com) add-in for Microsoft Excel ® , and agreement was assessed non-parametrically by Spearman rank correlation coeffi cient. Polynomial curve fi tting was used for value comparison. Continuous variables are described as means 8 standard deviation. Categorical clinical demographics are described as actual numbers and percentages of the total population.
Results
The demographic and cardiac risk factors for the study population are summarised in table 1 . The correlation between 2nd-and 3rd-generation assays is given in fi gure 1 showing excellent agreement (r = 0.99 Spearman, 95% confi dence interval, CI, 0.99-1.0; p ^ 0.0001, n = 153) across the whole data set; however, a curvilinear relationship was demonstrated ( fi g. 1 ) between the two assay generations across the whole analytical range. CABG = Coronary artery bypass graft; IDDM = insulin-dependent diabetes mellitus; IHD = ischaemic heart disease; NIDDM = non-insulin-dependent diabetes mellitus. .
Discussion
The present study demonstrates no signifi cant difference in cTnT concentrations between the detection limit of 0.01 and 0.2 g/l, but shows a non-linear relationship at higher 2nd-generation cTnT concentrations ( 1 0.2 g/l). Current guidelines suggest that the reference range for cardiac troponin of an apparently healthy population should be at the 99th percentile and have a coeffi cient of variation of 10% [1] . However in reality, no commercial assay reaches this target [8] . In a study of 696 healthy adults [9] , the lower limit of detection was found to be 0.01 g/l, the 99th percentile was 0.01 g/l with a 10% coeffi cient of variation at 0.03 g/l. The recalibration of the Elecsys cTnT assay using human recombinant cTnT rather than bovine cTnT for calibration material does not cause alterations to the proposed detection limit or the 99th percentile. A cut-off value of 0.1 g/l for AMI was proposed using the 2nd-generation assay [10] . With improvements to the precision and the recent redefi nition of AMI [1] , a cut-off value of 0.05 g/l is recommended for the diagnosis of AMI when using the 3rd-generation assay [11] . Furthermore, a study comparing the 2nd-generation with the new, 3rd-generation cTnT assay in 750 patients admitted to the coronary care unit [7] demonstrated that 35% more patients were classifi ed as having AMI on admission with the 3rd-generation assay. The 3rd-generation assay also identifi ed a 10% larger low-risk group of patients with cTnT in the range from 0.01 to 0.02 g/l who demonstrated signs of very minor myocardial necrosis [7] .
The change in assay calibration has the largest impact on risk stratifi cation cut-offs at values higher than 0.2 g/l. In the FRISC study [12] , the risk of cardiac events (cardiac death or myocardial infarction) at 5 months in unstable coronary artery disease was assessed according to cTnT quintiles. The lowest two risk groups (cTnT ! 0.06 g/l, 4.3% risk, and cTnT 0.06-0.18 g/l, 10.5% risk) are unaffected by the assay change. The highrisk group -the three highest quintiles correspond to 0.18-0.62 g/l and above (risk 16.1%) -will now readjust to 0.18-0.38 g/l and above. In this study, the greatest individual risk was seen in patients in the band from 0.62 to 2.12 g/l (20% risk) which now correspond to 0.38-0.9 g/l in the 3rd-generation assay. It has been demonstrated that a cTnT 6 2.8 g/l can predict a left-ventricular ejection fraction of ! 40% with 100% sensitivity and 92.9% specifi city [13] . Using the new 3rd-generation assay, a cTnT of 1 1.1 g/l will theoretically predict a leftventricular ejection fraction of ! 40% with similar sensitivity and specifi city. Furthermore, the 3rd-generation assay identifi es a 10% larger low-risk group with very minor cTnT ( 1 0.01-0.02 g/l) elevations when using the 3rd-generation assay and is probably due to improvement in the precision at this level [6] .
Conclusion
The risk classifi cation cut-offs currently in use or proposed for cTnT in the range 0.01-0.05 g/l are unaffected by the change in assay calibration. Previously reported values above 0.2 g/l will be reduced. 
